Literature DB >> 23059849

Medullary thyroid carcinoma (MTC) and RET proto-oncogene: mutation spectrum in the familial cases and a meta-analysis of studies on the sporadic form.

Gisella Figlioli1, Stefano Landi2, Cristina Romei3, Rossella Elisei4, Federica Gemignani5.   

Abstract

Medullary thyroid carcinoma (MTC) is an uncommon malignant tumor arising from the calcitonin-producing parafollicular cells (C cells) of thyroid. It accounts for 5-10% of all thyroid cancers, and it mostly occurs as a sporadic entity (sMTC), but a familial pattern (fMTC) is also possible. RET proto-oncogene germline mutations are crucial for the onset and the progression of fMTC, and the occurrence of single nucleotide polymorphisms could predispose to the sporadic form. In order to clarify the role of this gene in MTC, we carefully reviewed the PubMed database using appropriate terms. First, we summarized current knowledge of the germline RET mutations, mutation spectrum, and prevalence. We then performed a meta-analysis on the available case-control association studies for sMTC. Finally, we carried out in silico predictions of the best associated variants in the attempt to better define their role in the disease. To date, a total of 39 different RET germline mutations have been identified in fMTC families. The most affected codons are 609, 611, 618, 620 (exon 10) and 634 (exon 11), encoding for the extracellular cysteine-rich domain, and codons 768 (exon 13) and 804 (exon 14) of the intracellular tyrosine kinase domain. Six polymorphisms with at least three studies were included in the meta-analysis (A45A [rs1800858], G691S [rs1799939], L769L [rs1800861], S836S [rs1800862], S904S [rs1800863], and IVS1-126G>T [rs2565206]). The meta-analysis demonstrated a modest association of sMTC susceptibility with S836S and a strong association with the IVS1-126G>T polymorphism. Besides RET polymorphisms, we also investigated the role of a few other low-penetrance alleles of genes involved in the RET pathway or in xenobiotic metabolism, but none of these were confirmed. Thus, despite the well-known molecular basis of fMTC, the genetic variants of the sporadic form are still poorly understood, and functional analyses are needed to better understand the consequence of such RET variants and to improve our knowledge on the disease.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23059849     DOI: 10.1016/j.mrrev.2012.09.002

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  27 in total

1.  Identification and characterization of two novel germline RET variants associated with medullary thyroid carcinoma.

Authors:  A L Silva; F Carmo; M M Moura; R Domingues; C Espadinha; V Leite; B Cavaco; M J Bugalho
Journal:  Endocrine       Date:  2015-03-01       Impact factor: 3.633

2.  Quantitative assessment of the association between L769L and S836S polymorphisms at RET gene and medullary thyroid carcinoma risk.

Authors:  Yuanqi Zhang; Sanming Wang; Xiaodong Chen; Shengchao Huang; Jianwen Li
Journal:  Tumour Biol       Date:  2014-04-04

3.  The rare intracellular RET mutation p.S891A in a Chinese Han family with familial medullary thyroid carcinoma.

Authors:  Xiao-Ping Qi; Rong-Xin Zhang; Jin-Lin Cao; Zhen-Guang Chen; Hang-Yang Jin; Ren-Rong Yang
Journal:  J Biosci       Date:  2014-06       Impact factor: 1.826

Review 4.  Molecular genetics of thyroid cancer.

Authors:  Maha Rebaї; Ahmed Rebaї
Journal:  Genet Res (Camb)       Date:  2016-05-13       Impact factor: 1.588

5.  Modulatory Role of Single Nucleotide Polymorphisms of Distinct Genetic Pathways on Clinical Behavior of Medullary Thyroid Carcinoma.

Authors:  Vasudha Mishra; Pradnya Kowtal; Pallavi Rane; Rajiv Sarin
Journal:  Asian Pac J Cancer Prev       Date:  2020-05-01

6.  2012 European thyroid association guidelines for genetic testing and its clinical consequences in medullary thyroid cancer.

Authors:  R Elisei; M Alevizaki; B Conte-Devolx; K Frank-Raue; V Leite; G R Williams
Journal:  Eur Thyroid J       Date:  2012-12-19

7.  Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease Aggressiveness.

Authors:  Rachel K Voss; Lei Feng; Jeffrey E Lee; Nancy D Perrier; Paul H Graham; Samuel M Hyde; Frances Nieves-Munoz; Maria E Cabanillas; Steven G Waguespack; Gilbert J Cote; Robert F Gagel; Elizabeth G Grubbs
Journal:  J Clin Endocrinol Metab       Date:  2017-08-01       Impact factor: 5.958

8.  Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma.

Authors:  Lauren Fishbein; Ignaty Leshchiner; Vonn Walter; Ludmila Danilova; A Gordon Robertson; Amy R Johnson; Tara M Lichtenberg; Bradley A Murray; Hans K Ghayee; Tobias Else; Shiyun Ling; Stuart R Jefferys; Aguirre A de Cubas; Brandon Wenz; Esther Korpershoek; Antonio L Amelio; Liza Makowski; W Kimryn Rathmell; Anne-Paule Gimenez-Roqueplo; Thomas J Giordano; Sylvia L Asa; Arthur S Tischler; Karel Pacak; Katherine L Nathanson; Matthew D Wilkerson
Journal:  Cancer Cell       Date:  2017-02-02       Impact factor: 31.743

Review 9.  Thyroid C-Cell Biology and Oncogenic Transformation.

Authors:  Gilbert J Cote; Elizabeth G Grubbs; Marie-Claude Hofmann
Journal:  Recent Results Cancer Res       Date:  2015

Review 10.  Toxicogenomics and cancer susceptibility: advances with next-generation sequencing.

Authors:  Baitang Ning; Zhenqiang Su; Nan Mei; Huixiao Hong; Helen Deng; Leming Shi; James C Fuscoe; William H Tolleson
Journal:  J Environ Sci Health C Environ Carcinog Ecotoxicol Rev       Date:  2014       Impact factor: 3.781

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.